This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I



I

in which

R is H, X, A, X-CO- or A-CO-,

R^1 is H, =O, Hal, X, A, OH, OA, A-COO-, A-CONH-, A-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, -O$(CH_2)_m$COOH or -O$(CH_2)_m$OA,

R^2 is H, Hal or A,

~~R^3 is a monocyclic saturated, unsaturated or aromatic heterocyclic radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, CN, $(CH_2)_n$OH, NR^4R^5, =NH, =N-OH, =N-OA, COOA and/or carbonyl oxygen (=O), or $CONR^4R^5$,~~ is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl, 4*H*-1,4-oxazin-4-yl,

furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl or pyrazinyl,

optionally mono- or disubstituted by Hal, OA, OH, COOA and/or A, or $CONR^4R^5$,

R^2 and R^3	together are alternatively -CH=CH-NH- or $-CH_2-CH_2-NH$, where one H atom may be replaced by A-CO- or A-O-CO-,
R^4 and R^5,	independently of one another, are H or A, or
R^4 and R^5	together are alternatively an alkylene chain having 3, 4 or 5 carbon atoms, which may also be substituted by A, Hal, OA and/or carbonyl oxygen (=CO),
X	is aryl, arylalkyl, Het or Het-alkyl,
aryl	is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2-COOH$ or $-OCH_2-COOH$,
Het	is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, benzyl, cycloalkyl, OH, NH_2, $NHCONH_2$, NO_2, CN, $-CH_2-COOH$, $-CH_2-CONH_2$, NHCOA, NR^3SO_2A, CHO, SO_2NH_2, SO_2A and/or carbonyl oxygen,
A	is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
Hal	is F, Cl, Br or I,
m	is 1, 2, 3, 4, 5 or 6,
n	is 0, 1, 2, 3, 4 , 5 or 6,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 2. **(Previously Presented)** Compounds according to Claim 1, in

which

R is H or A,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 3. **(Canceled)**

Claim 4. **(Canceled)**

Claim 5. **(Currently Amended)** Compounds according to Claim 1, in which

R is H, X, A, X-CO- or A-CO-,

R^1 is H, =O, Hal, X, A, OH, OA, A-COO-, A-CONH-, A-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, -O$(CH_2)_m$COOH or -O$(CH_2)_m$OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl or pyrazinyl,

optionally mono- or disubstituted by Hal, OA, OH, COOA and/or A,

or

$CONR^4R^5$,

R^4 and R^5,	independently of one another, are H or A, or
R^4 and R^5	together are alternatively an alkylene chain having 3, 4 or 5 carbon atoms,
X	is aryl, arylalkyl, Het or Het-alkyl,
aryl	is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2$-COOH or $-OCH_2$-COOH,
Het	is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, benzyl, cycloalkyl, OH, NH_2, $NHCONH_2$, NO_2, CN, $-CH_2$-COOH, $-CH_2$-$CONH_2$, NHCOA, NR^3SO_2A, CHO, SO_2NH_2, SO_2A and/or carbonyl oxygen,
A	is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F,
Hal	is F, Cl, Br or I,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 6. (**Previously Presented**) Compounds according to Claim 1, in which

R	is H or A,
R^1	is H, OH, OA, O-allyl, O-propargyl, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, $-O(CH_2)_mCOOH$ or $-O(CH_2)_mOA$,
R^2	is H, Hal or A,
R^3	is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl, 3-oxo-2*H*-pyridazin-2-yl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl or pyrazinyl,

optionally mono- or disubstituted by Hal, OA, OH, COOA and/or A, or $CONR^4R^5$,

R^4 and R^5 together are an alkylene chain having 3, 4 or 5 carbon atoms,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

or ~~and~~ pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 7. **(Previously Presented)** Compounds according to Claim 1 in which

R is H, X, A, X-CO- or A-CO-,

R^1 is H, =O, Hal, X, A, OH, OA, A-COO-, A-CONH-, A-CONA-, N_3, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, $CON(A)_2$, O-allyl, O-propargyl, O-benzyl, =N-OH, =N-OA, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, -O$(CH_2)_m$COOH or -O$(CH_2)_m$OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 3-iminomorpholin-4-yl, 2-iminoimidazolidin-1-yl, 2-imino-1*H*-pyrazin-1-yl, 2,6-dioxopiperidin-1-yl, 2-oxopiperazin-1-yl, 2,6-dioxopiperazin-1-yl, 2,5-dioxopyrrolidin-1-yl, 2-oxo-1,3-oxazolidin-3-yl, 3-oxo-2*H*-pyridazin-2-yl, 2-caprolactam-1-yl (= 2-oxoazepan-1-yl), 2-azabicyclo[2.2.2]octan-3-on-2-yl, 5,6-dihydro-1*H*-pyrimidin-2-oxo-1-yl, 2-oxo-1,3-oxazinan-3-yl or 4*H*-1,4-oxazin-4-yl,

X is aryl, arylalkyl, Het or Het-alkyl,

aryl is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A,

-CH_2-COOH or -OCH_2-COOH,

Het is a mono- or bicyclic saturated, unsaturated or aromatic heterocyclic radical having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, benzyl, cycloalkyl, OH, NH_2, $NHCONH_2$, NO_2, CN, -CH_2-COOH, -CH_2-$CONH_2$, NHCOA, NR^3SO_2A, CHO, SO_2NH_2, SO_2A and/or carbonyl oxygen,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 8. **(Previously Presented)** Compounds according to Claim 1, in which

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 9. **(Previously Presented)** Compounds according to Claim 1, in which

R^1 is H, OH, OA, O-allyl, O-propargyl, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, -$O(CH_2)_m$COOH or -$O(CH_2)_m$OA,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 10. **(Previously Presented)** Compounds according to Claim 1, in which

A is unbranched or branched alkyl having 1-6 carbon atoms,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 11. **(Previously Presented)** Compounds according to Claim 1, in which

R is H or A,

R^1 is H, OH, OA, O-allyl, O-propargyl, $OCH_2CH(OH)CH_2OH$, A-O-CO-$(CH_2)_m$-O-, -$O(CH_2)_m$COOH or -$O(CH_2)_m$OA,

R^2 is H, Hal or A,

R^3 is 2-oxopiperidin-1-yl, 2-oxopyrrolidin-1-yl, 2-oxo-1*H*-pyridin-1-yl, 3-oxomorpholin-4-yl, 4-oxo-1*H*-pyridin-1-yl, 2-oxo-1*H*-pyrazin-1-yl, 2-oxoimidazolidin-1-yl, 2-oxopiperazin-1-yl or 3-oxo-2*H*-pyridazin-2-yl,

optionally monosubstituted by A, OH or COOA,

A is unbranched, branched or cyclic alkyl having 1-10 carbon atoms, in which, in addition, 1-7 H atoms may be replaced by F,

Hal is F, Cl, Br or I,

or pharmaceutically acceptable salts, stereoisomers or mixtures thereof in all ratios.

Claim 12. **(Previously Presented)** Compounds according to Claim 1

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-1*H*-pyrazin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxopiperidin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-fluor-4-(2-oxo-2*H*-pyridin-1-yl)-phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2S,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxopiperidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(2-oxopiperidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(2-oxopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[1-acetyl-2,3-dihydro-1*H*-indol-5-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-ethoxycarbonyl-1*H*-indol-5-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methoxy-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propargyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propargyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-methyl-2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-propargyloxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(5-methyl-2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(2-methoxycarbonyl-4-hydroxypyrrolidin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-methyl-2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2S,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-methyl-2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[4-(6-methyl-3-oxo-2*H*-pyridazin-2-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-[(4-ethynylphenyl)]-2-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

or pharmaceutically acceptable salts, or stereoisomers or mixtures thereof in all ratios.

Claim 13. (Previously Presented) Process for the preparation of compounds of the formula I according to Claim1 or pharmaceutically acceptable salts or stereoisomers thereof, comprising reacting

a) a compound of the formula II



II

in which R is as defined in Claim 1,

is reacted with a chloroformate compound to give a carbamate compound intermediate,

and subsequently reacting said intermediate with a compound of the formula III



III

in which

R^1, R^2 and R^3 are as defined in Claim 1,

or

b) reacting a compound of the formula III with a compound of the formula IV



IV

in which

R is as defined in Claim 1,

or

c) reacting a compound of the formula V



V,

in which R^2 and R^3 are as defined in Claim 1,

with a compound of the formula VI



VI

in which

L is Cl, Br, I or a free or reactively functionally modified OH group, and

R and R^1 are as defined in Claim 1,

and/or converting a base or acid of the formula I is converted into one of its salts.

Claim 14. **(Canceled)**

Claim 15. **(Canceled)**

Claim 16. **(Previously Presented)** Medicaments comprising at least one compound of the formula I according to Claim 1, and/or pharmaceutically acceptable, salts, stereoisomers or mixtures thereof in all ratios, and, optionally, excipients and/or adjuvants.

Claim 17. **(Canceled)**

Claim 18. **(Currently Amended)** A method for the treatment of thromboses, myocardial infarction, arteriosclerosis, apoplexia, angina pectoris, restenosis after angioplasty, or claudicatio intermittens, ~~migraine, tinnitus, tumours, tumour diseases and/or tumour metastases,~~ comprising administering a compound according to Claim 1, ~~in~~or a salt thereof, or stereoisomer or mixture thereof, and optionally a further medicament active ingredient, to a host in need thereof.

Claim 19. **(Canceled)**

Claim 20. **(Canceled)**

Claim 21. **(Previously Presented)** A pharmaceutical composition comprising a compound according to Claim 1, a salt, stereoisomer or mixture thereof, and a pharmaceutically acceptable carrier.